Anti-VIM Antibody, Non-Fucosylated (BioBet-486ZP) (CAT#: BioBet-486ZP) Datasheet

VIM

Vimentin

This gene encodes a type III intermediate filament protein. Intermediate filaments, along with microtubules and actin microfilaments, make up the cytoskeleton. The encoded protein is responsible for maintaining cell shape and integrity of the cytoplasm, and stabilizing cytoskeletal interactions. This protein is involved in neuritogenesis and cholesterol transport and functions as an organizer of a number of other critical proteins involved in cell attachment, migration, and signaling. Bacterial and viral pathogens have been shown to attach to this protein on the host cell surface. Mutations in this gene are associated with congenital cataracts in human patients. [provided by RefSeq, Aug 2017]

Pritumumab; 499212-74-7; CLN G11; CLNHII; CLNIgG; ACAII; VIM; vimentin; FLJ36605

Plasma membrane, Nucleus, Cytoskeleton

Diseases associated with VIM include Cataract 30, Multiple Types and Cataract 30.

Its related pathways are Cytoskeleton remodeling Neurofilaments and Apoptosis and survival Caspase cascade.

Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally.

Cancer antibody; Controls and Markers antibody; Developmental Biology antibody; Neuroscience antibody; Signaling Transduction antibody; Cancer-associated fibroblast antibody; CAF Marker antibody; EMT Study antibody; Mesenchymal Markers antibody; Fibroblast Marker antibody; Muller Cell Marker antibody; Sarcoma Marker antibody

Filament disassembly during mitosis is promoted by phosphorylation at Ser-55 as well as by nestin (By similarity). One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is enhanced during cell division, at which time vimentin filaments are significantly reorganized. Phosphorylation by PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by CDK5 during neutrophil secretion in the cytoplasm. Phosphorylated by STK33. O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status. S-nitrosylation is induced by interferon-gamma and oxidatively-modified low-densitity lipoprotein (LDL(ox)) possibly implicating the iNOS-S100A8/9 transnitrosylase complex.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

BioBet-486ZP

Human

Human

ADCC-enhanced Pritumumab is a non-fucosylated anti-VIM therapeutic biobetter antibody.

Cancers

Cancers